Prevalence of Anemia in Patients with Chronic Kidney Disease in Baghdad City: A Cross-Sectional Study
Keywords:
Anemia, chronic kidney disease, prevalence, hemoglobinAbstract
Background: Anemia is a common complication of chronic kidney disease (CKD) with significant health implications. This study aimed to determine the prevalence of anemia among patients with CKD in Baghdad, Iraq, and to identify associated clinical and laboratory parameters across different stages of CKD.
Methods: A cross-sectional study was conducted from June 2024 to January 2025 in a private hospital in Baghdad. A total of 462 adult CKD patients were enrolled. Demographic data, medical history, and laboratory parameters were collected. Anemia was defined according to WHO criteria (hemoglobin <13 g/dL in males and <12 g/dL in females). CKD was staged according to estimated glomerular filtration rate (eGFR) using the CKD-EPI equation.
Results: The overall prevalence of anemia was 67.5% among CKD patients, with increasing rates corresponding to advancing CKD stages: 28.6% in stage 1, 43.7% in stage 2, 62.9% in stage 3, 86.3% in stage 4, and 94.7% in stage 5. Mean hemoglobin levels showed progressive decline with worsening kidney function (13.1±1.6 g/dL in stage 1 vs. 8.7±1.4 g/dL in stage 5, p<0.001). Multivariate analysis identified reduced eGFR, female gender, diabetes mellitus, and low transferrin saturation as independent predictors of anemia in CKD patients.
Conclusion: Anemia is highly prevalent among CKD patients in Baghdad, with rates that exceed some international reports. The strong association with declining renal function underscores the need for routine anemia screening, particularly in advanced stages of CKD. Targeted interventions focusing on high-risk groups may improve outcomes in this vulnerable population.
References
1. Al-Saedy AJ, Al-Kahichy HR. Prevalence of Anemia in Patients with Chronic Kidney Disease at Baghdad Teaching Hospital. Iraqi J Hematol. 2023;12(1):18-25.
2. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva: World Health Organization; 2011.
3. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):279-335.
4. Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713-735.
5. Afshar R, Sanavi S, Salimi J, Ahmadzadeh M. Hematological profile of chronic kidney disease (CKD) patients in Iran, in pre-dialysis stages and after initiation of hemodialysis. Saudi J Kidney Dis Transpl. 2010;21(2):368-371.
6. Shaheen FA, Souqiyyeh MZ, Al-Attar BA, et al. Prevalence of anemia in predialysis chronic kidney disease patients. Saudi J Kidney Dis Transpl. 2011;22(3):456-463.
7. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 2003;63(5):1908-1914.
8. Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9(1).
9. Kazmi WH, Kausz AT, Khan S, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis. 2001;38(4):803-812.
10. Al-Kindi SG, Mahmoud AF, Hassan A, et al. Anemia in patients with chronic kidney disease in Qatar: a prospective cohort study. Qatar Med J. 2019;2019(3):19.
11. Awan AA, Walther CP, Richardson PA, Shah M, Winkelmayer WC, Navaneethan SD. Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease. Nephrol Dial Transplant. 2021;36(1):129-136.
12. Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol. 2017;18(1):345.
13. Fishbane S, Spinowitz B. Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018. Am J Kidney Dis. 2018;71(3):423-435.
14. Ulasi II, Ijoma CK, Kalu OA. High prevalence and poor knowledge of chronic kidney disease in a post-conflict area: a population-based study from rural Southern Nigeria. Nephron Clin Pract. 2018;138(2):110-119.
15. Sittichanbuncha Y, Sricharoen P, Tangkulpanich P, Sawanyawisuth K. The appropriate hemoglobin cut-off value for detecting increased risk for chronic kidney disease: a multicenter study in Thailand. J Epidemiol. 2015;25(5):381-387.
16. Mohammed AA, Abdalrahim MA, Jasim KA. Comparative Study of Hepcidin as a Key Regulator of Iron Metabolism in Hemodialysis Patients with and without Iron Disorders. Baghdad Sci J. 2022;19(1):125-133.
17. Kanbay M, Perazella MA, Kasapoglu B, Koroglu M, Covic A. Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management. Blood Purif. 2010;29(1):1-12.
18. Mercadal L, Metzger M, Haymann JP, et al. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS One. 2014;9(6)
19. Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care. 2003;26(4):1164-1169.
20. Ganz T, Nemeth E. Iron balance and the role of hepcidin in chronic kidney disease. Semin Nephrol. 2016;36(2):87-93.
21. Agarwal AK. Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly. J Am Med Dir Assoc. 2006;7(9 Suppl)
22. Al-Ali HS, Abdalwahid RM, Jasim AY. Patterns of anemia and associated factors in patients with chronic kidney disease in Baghdad. Iraqi Med J. 2023;7(2):45-53.
23. Ryu SR, Park SK, Jung JY, et al. The prevalence and management of anemia in chronic kidney disease patients: result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). J Korean Med Sci. 2017;32(2):249-256.
24. Thorp ML, Johnson ES, Yang X, Petrik AF, Platt R, Smith DH. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology (Carlton). 2009;14(2):240-246.
25. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631-1634.
26. Enia G, Panuccio V, Cutrupi S, et al. Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2007;22(2):538-544.
27. Al-Rubai HA, Jasim TM, Al-Saedi AJ. Iron deficiency in non-dialysis chronic kidney disease: prevalence and predictors. Med J Babylon. 2024;21(1):12-19.
28. Farag YM, Keithi-Reddy SR, Mittal BV, et al. Anemia, inflammation and health-related quality of life in chronic kidney disease patients. Clin Nephrol. 2011;75(6):524-533.
29. St Peter WL, Guo H, Kabadi S, et al. Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent patients with chronic kidney disease and anemia in the United States. BMC Nephrol. 2018;19(1):67.
30. Abbas FM, Hussain MA, Mahdi ZS. Evaluation of anemia status in chronic kidney disease patients in Baghdad. Iraqi J Med Sci. 2022;20(1):32-38.
